Eli Lilly secures long-awaited FDA approval for its obesity pill. Here's what to know

Eli Lilly’s FDA approval for its oral GLP-1 drug acts as a primary fundamental catalyst, aligning with the strategic expansion of its pipeline and signaling a potential trend reversal from recent selling pressure. With the RSI at an oversold 22.97, the confluence of this positive regulatory news and a bullish MACD crossover suggests LLY is positioned for a mean-reversion move, provided it can reclaim the critical $975 resistance level. Fundamental filings indicate high operating margins, yet the $7.8 billion Centessa acquisition adds near-term cash burn, increasing reliance on the success of the new obesity pill to sustain valuation multiples. Traders should monitor for a volume-backed breakout above the $980 mark, which would clear the immediate overhead supply; conversely, a failure to hold the $930 support level could trigger a deeper flush despite the positive news, given the current technical weakness. Aggressive investors might consider initial long entries here with tight stops below $925, banking on the significant "volume vacuum" gap back toward the $1,020 psychological resistance as momentum accelerates.